Guanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

guanfacine 4 takeda, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 4.56 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

guanfacine 3 takeda, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

guanfacine 2 takeda, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack 오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

guanfacine 1 takeda, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

CONTROLOC IV INJECTION 40 mgvial 싱가포르 - 영어 - HSA (Health Sciences Authority)

controloc iv injection 40 mgvial

takeda pharmaceuticals (asia pacific) pte. ltd. - pantoprazole sodium eqv pantoprazole - injection - 40 mg/vial - pantoprazole sodium eqv pantoprazole 40 mg/vial

CONTROLOC TABLET 20 mg 싱가포르 - 영어 - HSA (Health Sciences Authority)

controloc tablet 20 mg

takeda pharmaceuticals (asia pacific) pte. ltd. - pantoprazole sodium sesquihydrate eqv pantoprazole - enteric coated tablet - 20 mg - pantoprazole sodium sesquihydrate eqv pantoprazole 20 mg

CONTROLOC TABLET 40 mg 싱가포르 - 영어 - HSA (Health Sciences Authority)

controloc tablet 40 mg

takeda pharmaceuticals (asia pacific) pte. ltd. - pantoprazole - enteric coated tablet - 40 mg - pantoprazole 40 mg

PREVACID CAPSULE 30 mg 싱가포르 - 영어 - HSA (Health Sciences Authority)

prevacid capsule 30 mg

takeda pharmaceuticals (asia pacific) pte. ltd. - lansoprazole - capsule - 30 mg - lansoprazole 30 mg

ALBOTHYL VAGINAL SUPPOSITORY 90 mg 싱가포르 - 영어 - HSA (Health Sciences Authority)

albothyl vaginal suppository 90 mg

takeda pharmaceuticals (asia pacific) pte. ltd. - policresulen - suppository - 90 mg - policresulen 90 mg

FAKTU SUPPOSITORY 싱가포르 - 영어 - HSA (Health Sciences Authority)

faktu suppository

takeda pharmaceuticals (asia pacific) pte. ltd. - cinchocaine hcl; policresulen - suppository - 2.5 mg - cinchocaine hcl 2.5 mg; policresulen 100 mg